

Phase II (New Entities)**Allergy Immunotherapy Tablet³***Dust Mite Allergies***Allergy Immunotherapy Tablet³***Ragweed Allergies***AMPAkine***ADHD**Depression***CDK Inhibitor***Cancer***CHK-1 Inhibitor***Cancer***CXCR2 Receptor Antagonist***COPD***Glycine Uptake Inhibitor***Alcohol Dependence**Schizophrenia***Mometasone/Oxymetazoline***Allergic Rhinitis***Pleconaril***Common Cold and Asthma Exacerbations***Preladenant***Parkinson's Disease***Protease Inhibitor (SCH 900518)***Hepatitis C***QAB/Mometasone Combination***Asthma**COPD***Robatumumab****(Anti-IGF-1R Antibody)***Cancer***Rolapitant***Emesis***Topical Antifungal***Onychomycosis***Phase II (Value Adding Projects)****NOXAFIL***I.V. Formulation***TEMODAR***Variety of Solid Tumors***Phase III (New Entities)****Acadesine***Ischemia-Reperfusion Injury***Allergy Immunotherapy Tablet³***Grass Pollen Allergies***Boceprevir***Hepatitis C***Esmirtazapine***Insomnia**Hot Flashes***Mometasone/Formoterol****Combination***Asthma**COPD***NOMAC/E2***Contraceptive***Thrombin Receptor Antagonist***Acute Coronary Syndrome**Secondary Prevention***Vicriviroc***HIV Infection***Phase III (Value Adding Projects)****Golimumab¹***Ulcerative Colitis***IMPLANON NXT***Contraception***INTEGRILIN***Early Acute Coronary Syndrome***NASONEX***Congestion**Rhinosinusitis***VYTORIN² - Outcomes Trials***SHARP - Renal Disease**IMPROVE-IT - Acute Coronary Syndrome***Regulatory Application Filed (New Entities)****Asenapine***Schizophrenia (U.S.)**Bipolar Mania Disorder (U.S.)***▶ Corifollitropin alfa***Controlled Ovarian Stimulation (EU)***Golimumab¹***Rheumatoid Arthritis**Ankylosing Spondylitis**Psoriatic Arthritis***Sugammadex***Anesthesia (U.S., Japan)***Regulatory Application Filed (Value Adding Projects)****ASMANEX***Asthma (Japan)***NOXAFIL***Serious Fungal Infections (U.S.)***PEGINTRON***Malignant Melanoma (U.S., EU)***REMERON***Anti-depressant (Japan)***TEMODAR***I.V. Formulation (U.S., EU, Japan)***Investor Contacts:**

Janet Barth (908) 298-7011

Joe Romanelli (908) 298-7904

▶ Phase advance**▶ Indication advance**¹ International rights only² J.V. with Merck³ North American rights only

The SGP Product Pipeline is solely intended to provide to investors general information regarding Schering-Plough projects in development and, for this reason, the information is not represented to be complete. Due to market factors and the nature of the development and approval process, the information - including the status of these projects - is subject to change. The Pipeline speaks only to the date hereof. Schering-Plough does not assume any duty to update this information.

"International Status" does not necessarily imply that the company will be marketing the compound in all major countries.

The trademarks indicated by CAPITAL LETTERS are the property of, licensed to, promoted or distributed by Schering-Plough, its subsidiaries or related companies.

Pipeline Updates

Phase III

Corifollitropin alfa

In December 2008, Schering-Plough announced the European Medicines Agency (EMA) had accepted for review its Marketing Authorization Application for Corifollitropin alfa, the company's experimental, sustained follicle stimulant being developed as a potential treatment in Controlled Ovarian Stimulation (COS) for the development of multiple follicles and pregnancy in women participating in an Assisted Reproductive Technology (ART) program.

Regulatory Application Filed

TEMODAR (TEMODAL)

In December 2008, Schering-Plough announced that the Committee for Medicinal Products for Human Use (CHMP) of the EMA had issued a positive opinion recommending approval of the intravenous (IV) formulation of TEMODAL (temozolomide) as an alternative to the already approved oral form of temozolomide in the EU.

The CHMP approved an oral sachet packaging presentation for TEMODAL Capsules in the EU. This delivery enhancement will help meet the needs of healthcare providers and patients in the treatment of certain types of brain tumors.

Approvals

ASMANEX (DPI)

Pediatric Asthma [U.S. 2/08]

AROLYCEM¹

Hypoglycemia due to hyperinsulinism [Japan 4/08]

BRIDION (Sugammadex)

Reversal of neuromuscular blockade [EU 7/08]

CAELYX¹

Multiple Myeloma [EU 11/07]

CLARINEX-D 12 Hour

Allergic Rhinitis with Congestion [U.S. 2/06]

GANIREST

Prevention of premature ovulation during controlled ovarian stimulation [Japan 7/08]

NASONEX

Allergic Rhinitis [Japan 7/08]

Unscented [EU 4/07]

NOXAFIL

Oropharyngeal Candidiasis (OPC) [U.S. 10/06, EU 11/06]

Prevention of Invasive Fungal Infections [U.S. 9/06, EU 11/06]

PEGINTRON/REBETOL

Weight-Based Dosing [U.S. 3/08]

HCV / HIV coinfection [EU 6/07]

REMICADE¹

Reduction of Ulcerative Colitis surgical procedures [EU 4/08]

Pediatric Crohn's Disease [EU 3/07]

Second-line Crohn's Disease [EU 10/06]

Psoriatic Arthritis Monotherapy [EU 3/06]

TEMODAR

Oral Sachet [EU 1/09]

Astrocytoma / Glioblastoma Multiforme [Japan 7/06]

VYTORIN²

Rosuvastatin data / labeling [U.S. 10/06]

Atorvastatin data / labeling [U.S. 3/06]

ZEMURON

Pediatric Indication [8/08]

ZETIA²

Lipid Lowering Monotherapy [Japan 4/07]

¹International rights only

²J.V. with Merck

³North American rights only

Worldwide Prescription Products

February 2009

Phase II (New Entities)

AIT (Dust Mite): an allergy immunotherapy in an oral tablet formulation for the treatment and prevention of dust mite allergies. In-licensed from ALK-Abello.

AIT (Ragweed): an allergy immunotherapy in an oral tablet formulation for the treatment and prevention of ragweed allergies. In-licensed from ALK-Abello.

AMPAkine: a glutaminergic for Attention Deficit Hyperactivity Disorder (ADHD) and Depression; Compounds from Cortex obtained via the OBS acquisition.

CDK Inhibitor: a cell-cycle inhibitor in development for various cancers.

CHK-1 Inhibitor: a cell-cycle inhibitor in development for various cancers.

CXCR2 Receptor Antagonist: a chemokine receptor antagonist being developed for COPD and asthma.

Glycine Uptake Inhibitor: a glycine uptake inhibitor in development for the treatment of schizophrenia and alcohol dependency.

Mometasone/Oxymetazoline: a nasal inhaled combination product containing the steroid mometasone furoate and the vasoconstrictor oxymetazoline being developed for allergic rhinitis.

Pleconaril: an intranasal spray being developed for the prevention of common cold symptoms and asthma exacerbations.

Preladenant: an oral adenosine 2A receptor antagonist in development for Parkinson's disease and movement disorders. Designated "Fast Track" status by the FDA.

Protease Inhibitor (SCH 900518): a next generation oral NS3 protease inhibitor for the treatment of hepatitis C virus infection. Designated "Fast Track" status by the FDA.

QAB/Mometasone Combination: a combination product containing the long-acting beta agonist QAB 149 with the steroid mometasone furoate being developed for asthma and COPD. Being developed in collaboration with Novartis.

Rolapitant: a NK-1 inhibitor for chemotherapy induced nausea and vomiting.

Robatumumab: an antibody directed against Insulin-like growth factor 1 R (IGF-1R) for various cancers, such as Ewing's sarcoma.

Topical Antifungal: a topical cyclized boronic acid complex that inhibits fungal leucyl-tRNA synthetase. Being developed as a topical antifungal agent for onychomycosis (fungal nail infection). In-licensed from Anacor.

Phase II (Value Adding Projects)

NOXAFIL: a triazole antifungal agent being developed as an IV solution for the treatment of serious fungal infections (EU). Designated "Fast Track" status by the FDA.

TEMODAR: an oral alkylating agent for the treatment of brain tumors being tested in a variety of solid tumors.

Phase III (New Entities)

Acadesine: an injectable adenosine regulating agent being studied for the prevention of ischemia/reperfusion injury in patients undergoing coronary artery bypass surgery (CABG). In-licensed from Pericor.

AIT (Grass): an allergy immunotherapy in an oral tablet formulation for the treatment and prevention of grass allergies. In-licensed from ALK-Abello.

Boceprevir: an oral NS3 protease inhibitor for the treatment of hepatitis C virus infection. Designated "Fast Track" status by the FDA.

Esmirtazapine: a serotonin and histamine receptor antagonist in development for primary insomnia and for the treatment of vasomotor symptoms (i.e. hot flashes) during menopause.

Mometasone/Formoterol: a combination product containing the steroid mometasone furoate (MF) and the long-acting beta-agonist formoterol (F). MFF is being developed in a metered-dose inhaler for the treatment of asthma and chronic obstructive pulmonary disease (COPD). MFF is being developed in collaboration with Novartis.

NOMAC/E2: a combined oral contraceptive containing norgestrel acetate (NOMAC) and the natural estrogen estradiol (E2) in a 24/4 regimen. In-licensed from Theramex.

Thrombin Receptor Antagonist: an oral thrombin receptor antagonist (TRA) that binds to the PAR-1 receptor to prevent thrombin-induced platelet aggregation. Being developed for acute coronary syndrome and secondary prevention of ischemic events in patients who have previously had a heart attack, stroke or have peripheral vascular disease. Designated "Fast Track" status by the FDA.

Vicriviroc: an oral chemokine (CCR5) co-receptor antagonist which blocks the entry of HIV into cells. In development for treatment-experienced HIV infection. Designated "Fast Track" status by the FDA.

Phase III (Value Adding Projects)

Golimumab: humanized monoclonal antibody directed against tumor necrosis factor-alpha (TNF- α) being developed in a once-monthly subcutaneous dosing form for ulcerative colitis. Partnered with Johnson & Johnson.

IMPLANON NXT: an injectable contraceptive being developed with a radio-opaque rod.

INTEGRILIN: an intravenous Glycoprotein IIb-IIIa inhibitor indicated for the treatment of patients with NSTEMI acute coronary syndrome and PCI being investigated in a double bolus regimen.

NASONEX: an inhaled nasal corticosteroid, mometasone furoate, being developed for congestion and rhinosinusitis.

VYTORIN: a combination of two cholesterol lowering medications, simvastatin and ZETIA (ezetimibe), is being evaluated in patients with kidney disease and acute coronary syndrome.

Regulatory Application Filed (New Entities)

Asenapine: an atypical antipsychotic being developed for the treatment of schizophrenia and bipolar mania disorder.

Corifollitropin alfa: a long-acting, injectable recombinant follicle stimulating hormone for controlled ovarian stimulation in women undergoing assisted reproductive treatment.

Golimumab: a humanized monoclonal antibody directed against tumor necrosis factor-alpha (TNF- α) being developed in a once-monthly subcutaneous dosing form for rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis. Partnered with Johnson & Johnson.

Sugammadex: a selective relaxant binding agent (SRBA) used to reverse neuromuscular blockade following surgical procedures.

Regulatory Application Filed (Value Adding Projects)

ASMANEX: an inhaled corticosteroid, mometasone furoate, indicated for the treatment of asthma.

NOXAFIL: a triazole antifungal agent being developed for the treatment of serious fungal infections.

TEMODAR: an oral alkylating agent for the treatment of brain tumors is being developed as an IV solution and in a single unit-dose oral sachet.

PEGINTRON: a covalent conjugate of recombinant alfa-2b interferon with monomethoxy polyethylene glycol (PEG) indicated for the treatment of the hepatitis C virus has been filed for the treatment of malignant melanoma.

REMERON: a tetracyclic antidepressant that increases the activity of norepinephrine and serotonin.